All News

Patients with intermediate and mild Parkinson disease, defined by a Hoehn & Yahr stage of 3 or less, experienced an additional deterioration in motor function with simvastatin compared with placebo while not taking medication at 24 months.

The increasing rate of melanoma diagnosis may not be due to actual disease, the authors of a new study posit; instead, it may be due to overdiagnosis of patients with an actual very low risk of death.

A study in Brazil found that delaying the start to the school day by an hour improved sleepiness and mood profile in children attending high school.

Population health brings an important lens to both oncology practice and research, said Neil Iyengar, MD, associate attending physician, breast medical service, Memorial Sloan Kettering Cancer Center.

A listeria outbreak has been linked to deli meats and cheeses; the World Health Organization announced that there has been a 90% drop in recent deaths in COVID-19 globally compared with 9 months ago; Eli Lilly was ordered to pay $176.5 million in a US migraine drug patent trial.

Patients with heart failure frequently suffer from fluid overload, and for those with heart failure with reduced ejection fraction (HFrEF) also suffering from septic shock—a condition often treated with fluids—more data are needed on outcomes following fluid administration.

Real-world patients with atopic dermatitis with dark skin types showed greater mean reduction in disease severity between baseline and 6 months with dupilumab compared with those with light skin types, whereas no differences were observed regarding severity reduction for methotrexate and ciclosporin.

This new report also shows the value of national databases tracking the use of ventilation support.

Patients with type 2 diabetes who use empagliflozin or sodium-glucose cotransporter 2 (SGLT2) inhibitors (SGLT2) long term were shown to have less kidney function loss.

Although the understanding of chronic graft-versus-host disease (GVHD) has improved in recent years, more work is needed to facilitate personalized treatments for patients after hematopoietic stem cell transplantation (HSCT).

Several known risk factors and prodromal features were associated with Parkinson disease, including traumatic brain injury and alcohol misuse, along with other comorbidities such as skin and gastrointestinal disorders.

A new report has found continuous glucose monitoring (CGM) may help reduce staff burden in the intensive care unit (ICU) by reducing the need for blood gas monitoring.

The investigators of a new study evaluated if nasal cytology was a reliable method to identify type 2 inflammation in patients who have chronic rhinosinusitis with nasal polyps (CRSwNP), which could then facilitate patient selection for biological drug utilization via endotypization.

An analysis of Medicaid coverage found that Mississippi was the only state not to provide coverage for human papillomavirus (HPV) vaccination in adults aged 27 to 45 years.

Abortion rights measures on the ballot saw victories in all 5 states; South Dakota voted to expand access to Medicaid; rates of inflammatory heart conditions were increased in people with the second dose of the Moderna COVID-19 vaccine.

A study found that the characteristics and location of epilepsy centers in the United States are associated with differences in presurgical testing for drug-0resistant epilepsy.

The new data suggest risdiplam can be a viable option for people with spinal muscular atrophy who cannot take or tolerate the 2 other approved disease-modifying therapies.

The FDA approved cemiplimab (Libtayo) in combination with platinum-based chemotherapy for the first-line treatment of advanced non–small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations.

Zanubrutinib is the latest of 3 Bruton tyrosine kinase (BTK) inhibitors approved for rare B-cell malignancies, such as Waldenström macroglobulinemia, a non-Hodgkin B-cell lymphoma (NHBCL); as a next-generation BTK inhibitor, zanubrutinib is designed to have less off-target effects.

While chimeric antigen receptor (CAR) T-cell therapy has offered a new option and improved outcomes for patients with advanced hematologic malignancies, the treatment approach has been associated with toxicities such as cytokine release syndrome (CRS), neurotoxicity, and hematotoxicity.

A phase 3 study showed Ferring’s RBX2660, an investigational microbiota-based live biotherapeutic, to be safe and significantly reduce recurrence of Clostridioides difficile infection (CDI) after antibiotic treatment, with a sustained response achieved through 6 months.

Nancy Reau, MD, section chief of hepatology at Rush University Medical Center, elaborates on survey results showing providers have varying awareness and understanding on guidelines for chronic liver disease.

A panel including several experts in cardiology discussed the ways that heart failure (HF) can be diagnosed and treated using the new 2022 AHA/ACC/HFSA Guidelines.

Patient-Centered Oncology Care® (PCOC) begins Wednesday in Tennessee with 2 days of discussions on how to achieve the related goals of closing health care disparities and eliminating barriers for patients.

Kashyap Patel, MD, president of Community Oncology Alliance and chief executive officer of Carolina Blood and Cancer Care Associates, previews the Patient-Centered Oncology Care® (PCOC) 2022 meeting happening this week in Nashville, Tennessee.

The Department of Veterans Affairs (VA) will give cancer claims priority when a new law takes effect in January 2023; Pfizer is looking to use its COVID-19 profits to grow other blockbusters; the probable loss of Medicaid coverage for millions next year is setting off debate.

Tochi M. Okwuosa, DO, cardiologist and director of cardio-oncology at Rush University Medical Center, delivered several presentations at the American Heart Association’s Scientific Sessions this year. Chief among them were the importance of cardiovascular health in cancer survivors and cardio-toxicity from cancer treatments.

Kausik K. Ray, MB ChB, MD, MPhil, is professor of public health and a consultant cardiologist at Imperial College London in the United Kingdom. At this year’s American Heart Association’s Scientific Sessions, he presented findings from a 4-year open-label extension study of inclisiran, a small interfering RNA that targets proprotein convertase subtilisin kexin type 9 to lower low-density lipoprotein cholesterol (LDL-C).